PRODUCT INFORMATION

BAW 2881

Item No. 18910

CAS Registry No.:	861875-60-7
Formal Name:	6-[(2-amino-4-pyrimidinyl)oxy]-N-[3-(trifluoromethyl)phenyl]-1-naphthalenecarboxamide
Synonym:	NVP-BAW 2881
MF:	$C_{22}H_{15}F_3N_4O_2$
FW:	424.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 226, 284 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BAW 2881 is supplied as a crystalline solid. A stock solution may be made by dissolving the BAW 2881 in the solvent of choice, which should be purged with an inert gas. BAW 2881 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of BAW 2881 in these solvents is approximately 30 mg/ml.

BAW 2881 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BAW 2881 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. BAW 2881 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BAW 2881 is a vascular endothelial growth factor receptor (VEGFR) inhibitor(IC_{50}s = 0.82, 0.037, and 0.42 µM for hVEGFR1, 2, and 3, respectively).[1] It inhibits Tie2 and RET with IC_{50} values of 0.65 and 0.41 µM, respectively, but demonstrates IC_{50} values greater than 10 µM toward a large panel of additional kinases.[1] BAW 2881 was shown to block VEGF-A-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells and lymphatic endothelial cells *in vitro*.[1] In a mouse model of psoriasis, both oral and topical administration of BAW 2881 reduced psoriasis-like inflammation in ear skin.[1] Topical application of BAW 2881 also reduced VEGF-A-induced vascular permeability and inhibited contact hypersensitivity reactions and UV-B-induced erythema in the skin of domestic pigs.[1]

Reference

1. Halin, C., Fahrngruber, H., Meingassner, J. G., *et al.* Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. *Am. J. Pathol.* **173(1)**, 265-277 (2008).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM